Abstract
It is now well appreciated that asthma is a chronic inflammatory disease of the airways; among the inflammatory cells that have been implicated in the asthmatic lesion are eosinophils and mast cells. Although these cells have the capacity to produce a number of distinct chemical mediators, the cysteinyl leukotrienes have recently been identified as important mediators of the asthmatic response. The leukotrienes are derived from arachidonic acid released from membrane phospholipids by the action of phospholipases. The archidonic acid so released in the presence of the 5-lipoxygenase (5-LO) activating protein becomes a substrate for the enzyme 5-LO. This enzyme catalyses the stereo-specific addition of molecular oxygen to arachidonic acid to form the product known as leukotriene A4. Leukotriene A4 subsequently becomes a substrate for one of two enzymes, leukotriene A4 epoxide hydrolase or LTC4 synthase. The former catalyses the formation of LTB4 while the later catalyses the formation of the cysteinyl leukotrienes. Thus the enzyme 5-LO is critically posed to serve as a regulator of leukotriene synthesis. 5-LO action is known to be regulated at a number of levels; the mechanisms include regulation of action of the mature protein and regulation of 5-LO gene transcription and translation; there is good reason to believe that all forms of 5-LO regulation are highly interdependent. In this regard we describe the presence and functional consequences of a series of naturally occuring mutations in 5-LO core promoter. These mutations modify gene transcription in vitro, and may have functional consequences in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 164-170 |
| Number of pages | 7 |
| Journal | Clinical and Experimental Allergy, Supplement |
| Volume | 28 |
| Issue number | 5 |
| Publication status | Published - 1998 Dec 18 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Pharmacogenetics of the 5-lipoxygenase pathway in asthma. / Silverman, E.; In, Kwang Ho; Yandava, C.; Drazen, J. M.
In: Clinical and Experimental Allergy, Supplement, Vol. 28, No. 5, 18.12.1998, p. 164-170.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacogenetics of the 5-lipoxygenase pathway in asthma
AU - Silverman, E.
AU - In, Kwang Ho
AU - Yandava, C.
AU - Drazen, J. M.
PY - 1998/12/18
Y1 - 1998/12/18
N2 - It is now well appreciated that asthma is a chronic inflammatory disease of the airways; among the inflammatory cells that have been implicated in the asthmatic lesion are eosinophils and mast cells. Although these cells have the capacity to produce a number of distinct chemical mediators, the cysteinyl leukotrienes have recently been identified as important mediators of the asthmatic response. The leukotrienes are derived from arachidonic acid released from membrane phospholipids by the action of phospholipases. The archidonic acid so released in the presence of the 5-lipoxygenase (5-LO) activating protein becomes a substrate for the enzyme 5-LO. This enzyme catalyses the stereo-specific addition of molecular oxygen to arachidonic acid to form the product known as leukotriene A4. Leukotriene A4 subsequently becomes a substrate for one of two enzymes, leukotriene A4 epoxide hydrolase or LTC4 synthase. The former catalyses the formation of LTB4 while the later catalyses the formation of the cysteinyl leukotrienes. Thus the enzyme 5-LO is critically posed to serve as a regulator of leukotriene synthesis. 5-LO action is known to be regulated at a number of levels; the mechanisms include regulation of action of the mature protein and regulation of 5-LO gene transcription and translation; there is good reason to believe that all forms of 5-LO regulation are highly interdependent. In this regard we describe the presence and functional consequences of a series of naturally occuring mutations in 5-LO core promoter. These mutations modify gene transcription in vitro, and may have functional consequences in vivo.
AB - It is now well appreciated that asthma is a chronic inflammatory disease of the airways; among the inflammatory cells that have been implicated in the asthmatic lesion are eosinophils and mast cells. Although these cells have the capacity to produce a number of distinct chemical mediators, the cysteinyl leukotrienes have recently been identified as important mediators of the asthmatic response. The leukotrienes are derived from arachidonic acid released from membrane phospholipids by the action of phospholipases. The archidonic acid so released in the presence of the 5-lipoxygenase (5-LO) activating protein becomes a substrate for the enzyme 5-LO. This enzyme catalyses the stereo-specific addition of molecular oxygen to arachidonic acid to form the product known as leukotriene A4. Leukotriene A4 subsequently becomes a substrate for one of two enzymes, leukotriene A4 epoxide hydrolase or LTC4 synthase. The former catalyses the formation of LTB4 while the later catalyses the formation of the cysteinyl leukotrienes. Thus the enzyme 5-LO is critically posed to serve as a regulator of leukotriene synthesis. 5-LO action is known to be regulated at a number of levels; the mechanisms include regulation of action of the mature protein and regulation of 5-LO gene transcription and translation; there is good reason to believe that all forms of 5-LO regulation are highly interdependent. In this regard we describe the presence and functional consequences of a series of naturally occuring mutations in 5-LO core promoter. These mutations modify gene transcription in vitro, and may have functional consequences in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0031766873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031766873&partnerID=8YFLogxK
M3 - Article
C2 - 9988463
AN - SCOPUS:0031766873
VL - 28
SP - 164
EP - 170
JO - Clinical and Experimental Allergy, Supplement
JF - Clinical and Experimental Allergy, Supplement
SN - 0960-2178
IS - 5
ER -